12.04.2015 • News

Takeda Said Offering $2.2 Billion to Settle Actos Lawsuits

Japanese pharmaceutical company Takeda has offered more than $2.2 billion to settle thousands of US lawsuits over the diabetes drug Actos, the news agency Bloomberg reports.

The proposal is said to provide for awards of about $275,000 in each of the more than 8,000 lawsuits filed over the drug, alleging that it caused bladder cancer. The plaintiffs claim that Takeda downplayed those concerns and misled regulators about the risks.

The first payout offered concerning Actos is said to be part of an effort by Takeda to avoid further jury verdicts such as the $9 billion award in a Louisiana case last year. A federal judge later slashed that amount to $36.8 million.

Some of the attorneys representing victims have told news agencies that the $2.2 billion settlement would be insufficient.

More than 3,500 of the pending Actos cases were consolidated before a federal judge in Louisiana. State courts in California, Illinois, Pennsylvania and West Virginia are said to be considering the remaining cases.

 

Book

Innovation Management in Sustainable Chemistry

Innovation Management in Sustainable Chemistry

Comprehensive resource on sustainable chemistry, bridging the skill gap between academic science education and innovation and entrepreneurship

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.